OncoTherapy Science (30O) Stock Statistics & Valuation Metrics
Total Valuation
OncoTherapy Science has a market cap or net worth of EUR 41.68M. The enterprise value is EUR 4.85B.
- Market Cap
- EUR 41.68M
- Enterprise Value
- EUR 4.85B
Share Statistics
OncoTherapy Science has 408,243,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 408,243,700
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
OncoTherapy Science’s return on equity (ROE) is -0.43 and return on invested capital (ROIC) is -37.01%.
- Return on Equity (ROE)
- -0.43
- Return on Assets (ROA)
- -0.39
- Return on Invested Capital (ROIC)
- -37.01%
- Return on Capital Employed (ROCE)
- -0.37
- Revenue Per Employee
- 17.58M
- Profits Per Employee
- -19.80M
- Employee Count
- 46
- Asset Turnover
- 0.34
- Inventory Turnover
- 12.73
Valuation Ratios
The current PE Ratio of OncoTherapy Science is -7.63. OncoTherapy Science’s PEG ratio is -0.30.
- PE Ratio
- -7.63
- PS Ratio
- 9.45
- PB Ratio
- 3.06
- Price to FCF
- 0.00
- Price to Operating Cash Flow
- 0.00
- PEG Ratio
- -0.30
Income Statement
In the last 12 months, OncoTherapy Science had revenue of 808.53M and earned -910.64M in profits. Earnings per share was -2.77.
- Revenue
- 808.53M
- Gross Profit
- 13.96M
- Operating Income
- -810.38M
- Pretax Income
- -908.48M
- Net Income
- -910.64M
- EBITDA
- -810.38M
- Earnings Per Share (EPS)
- -2.77
Cash Flow
In the last 12 months, operating cash flow was 0 and capital expenditures 0, giving a free cash flow of 0 billion.
- Operating Cash Flow
- 0
- Free Cash Flow
- 0
- Free Cash Flow per Share
- 0.00
Dividends & Yields
OncoTherapy Science pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 0.00%
- Earnings Yield
- -12.33%
Stock Price Statistics
- Beta
- 1.21
- 52-Week Price Change
- -25.96%
- 50-Day Moving Average
- 0.09
- 200-Day Moving Average
- 0.09
- Relative Strength Index (RSI)
- 48.06
- Average Volume (3m)
- ―
Important Dates
OncoTherapy Science upcoming earnings date is Jan 29, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 07, 2026
- Next Earnings Date
- Jan 29, 2027
- Ex-Dividend Date
- ―
Financial Position
OncoTherapy Science as a current ratio of 13.59, with Debt / Equity ratio of 0.00%
- Current Ratio
- 13.59
- Quick Ratio
- 13.22
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 2.58
- Interest Coverage Ratio
- -618.14
Taxes
In the past 12 months, OncoTherapy Science has paid 2.16M in taxes.
- Income Tax
- 2.16M
- Effective Tax Rate
- -0.00
Enterprise Valuation
OncoTherapy Science EV to EBITDA ratio is -5.56, with an EV/FCF ratio of 0.00.
- EV to Sales
- 6.46
- EV to EBITDA
- -5.56
- EV to Free Cash Flow
- 0.00
- EV to Operating Cash Flow
- 0.00
Balance Sheet
OncoTherapy Science has EUR 1.23B in cash and marketable securities with EUR 37.14M in debt, giving a net cash position of EUR 1.19B billion.
- Cash & Marketable Securities
- EUR 1.23B
- Total Debt
- EUR 37.14M
- Net Cash
- EUR 1.19B
- Net Cash Per Share
- EUR 2.92
- Tangible Book Value Per Share
- EUR 3.89
Margins
Gross margin is 2.19%, with operating margin of -106.36%, and net profit margin of -113.81%.
- Gross Margin
- 2.19%
- Operating Margin
- -106.36%
- Pretax Margin
- -113.53%
- Net Profit Margin
- -113.81%
- EBITDA Margin
- -116.21%
- EBIT Margin
- -116.21%
Analyst Forecast
The average price target for OncoTherapy Science is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -17.22%
- EPS Growth Forecast
- 26.49%
